ImClone in talks with secret suitor

Carl Icahn, CEO at ImClone, is turning his nose up at its recent offer from Bristol-Myers Squibb and the company now officially is saying the $60 bucks a share that the huge pharma company offered for ImClone was "inadequate."

Icahn apparently has been having tête-à-tête talks with a secret pharma mistress.

The company today released a statement saying that the CEO of a large pharmaceutical company has been wooing the company and that Icahn has had several discussions with said (well, unsaid) CEO of said (unsaid) company, which is making a cash offer of $70 per share. This brings the offer price to about $6.1 billion...a nice increase over the Bristol-Myers offer of about a billion dollars less.

ImClone will give its hush-hush friend two weeks for due diligence, but not for financing. In the meantime, have fun betting on who the interested party might be. Merck? GlaxoSmithKline? Eli Lilly? Novartis? Pfizer? Stay tuned.

- here's the press release
- read more at the Street Insider

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.